We are live on ! Find out more
PTIXW

Protagenic Therapeutics Warrant
PTIXW

Delisted

PTIXW was delisted on the 2nd of January, 2026.

Back to rankings

2 hedge funds and large institutions have $143K invested in Protagenic Therapeutics Warrant in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding

Funds holding: 1 → 2 (+1)

1.2% less ownership

Funds ownership: 3.45% → 2.25% (-1.2%)

45% less capital invested

Capital invested by funds: $260K → $143K (-$117K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
+1
Holders Change %
+100%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$316

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$526
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
1
Warberg Asset Management
Illinois
$143K -$526 -999 -0.3%
UBS Group
2
UBS Group
Switzerland
– +$316 +600 New

PTIXW Hedge Fund Activity: Q3 2021 in Review

2 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q3 2021, worth a combined $143K — down 45% from $260K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new PTIXW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $316. The largest seller was Warberg Asset Management, cutting an estimated $526.

  • 2 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q3 2021, up from 1 in Q2 2021.
  • Funds reported $143K of Protagenic Therapeutics Warrant stock for Q3 2021, down 45% quarter-over-quarter.
  • 1 fund opened new Protagenic Therapeutics Warrant positions in Q3 2021 and 0 closed out, a net change of +1 holder.
  • The largest Protagenic Therapeutics Warrant buyer in Q3 2021 was UBS Group, an estimated $316 added.
  • The largest Protagenic Therapeutics Warrant seller in Q3 2021 was Warberg Asset Management, an estimated $526 sold.

Based on aggregated 13F filings for Q3 2021.